Home ›
Breast Cancer Trials ›
NCT07088263
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of advanced breast cancer progressive after standard treatment.
Trial Details
NCT ID NCT07088263
Phase PHASE3
Sponsor Sun Yat-sen University
Status RECRUITING
Cancer Type Breast Cancer
Interventions Gemcitabine, Vinorelbine, Eribulin, or Utidelone
Locations (sample) Guangzhou, Guangdong, China|23.11667,113.25
Key Eligibility Criteria
Understands and voluntarily signs the informed consent form. ECOG PS of 0 or 1. Expected survival: \>3 months Histologically or cytologically confirmed advanced invasive breast cancer.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Breast Cancer Trials on Trialify →